AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IKNA
  4. [D] Ikena Oncology, Inc. SEC Filing

[D] Ikena Oncology, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock IKNA logo
Ikena Oncology

NASDAQ:IKNA

IKNA Rankings

#7292 Ranked by Market Cap
N/A Ranked by Dividends

IKNA Latest News

Jul 25, 2025
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Jul 23, 2025
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Jul 15, 2025
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Dec 23, 2024
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Nov 7, 2024
Ikena Oncology Reports Third Quarter 2024 Financial Results

IKNA Latest SEC Filings

Jul 25, 2025
[8-K] Ikena Oncology, Inc. Reports Material Event
Jul 24, 2025
[10-Q] Ikena Oncology, Inc. Quarterly Earnings Report
Jul 24, 2025
[8-K] Ikena Oncology, Inc. Reports Material Event
Jul 22, 2025
[8-K] Ikena Oncology, Inc. Reports Material Event
Jul 16, 2025
[8-K] Ikena Oncology, Inc. Reports Material Event

IKNA Stock Data

57.81M
35.00M
4.55%
87.76%
0.29%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BOSTON